中国肺癌杂志2018，Vol.21Issue(5)：419-424,6.DOI:10.3779/j.issn.1009-3419.2018.05.11
KRAS突变的非小细胞肺癌的研究进展
Research Progress of KRAS Mutation in Non-small Cell Lung Cancer
刘蕾 1魏素菊1
作者信息
- 1. 050011 石家庄,河北医科大学第四医院肿瘤内科
- 折叠
摘要
Abstract
Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for 80%-85% of all patients with lung cancer, the majority of patients with lung cancer at the time of diagnosis is in the advanced stage. The development of target therapy based on has changed the mode of treatment in patients with advanced NSCLC. In NSCLC, epidermal growth factor receptor mutation (EGFR) fusion with echinoderm microtubule-associated pro-tein-like4-anaplastic lymphoma kinase (EML4-ALK) has been shown to be a powerful biomarker. It is well known that KRAS is also NSCLC one of the most common mutations in oncogenes,although more than 20 years ago KRAS mutation was found in NSCLC.At present,although there are many drugs used to treat NSCLC patients with KRAS mutation,there is no selective or specific inhibitor for the direct elimination of KRAS activity.NSCLC patients with KRAS mutation have poor responsive-ness to most systemic therapy. However, individualized therapy for activated signaling pathways with targeted drugs has a good effect on the prognosis of NSCLC patients with KRAS mutation.In addition,the prognostic and predictive role of KRAS muta-tion in NSCLC remains unclear.In this review,we focus on the research progress of NSCLC with KRAS mutation,including molecular biology,clinicopathological features,prognosis and prediction of KRAS mutation,which will help to improve the understanding of NSCLC in KRAS mutation.关键词
KRAS/肺癌/预测/预后/靶向Key words
KRAS/Lung neoplasms/Predictive/Prognostic/Target引用本文复制引用
刘蕾,魏素菊..KRAS突变的非小细胞肺癌的研究进展[J].中国肺癌杂志,2018,21(5):419-424,6.
